Calidi Biotherapeutics

CLDINYSE United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$3.962 M

$1.62 -9.50%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$19.9M

Loss-making

Shares outstanding

10,895,725

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#155BioAtlaBCAB$5.74M
#156BiomXPHGE$4.25M
#157Calidi BiotherapeuticsCLDI$3.96M
#158Silexion TherapeuticsSLXN$1.99M
#159Scinai ImmunotherapeuticsSCNI$1.23M

Where these numbers come from

Share counts and financials for Calidi Biotherapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.